降钙素联合骨化三醇胶丸对糖尿病合并骨质疏松症的影响

㊃药物研究㊃

∗通信作者:徐剡,Email:oycxol@

降钙素联合骨化三醇胶丸对糖尿病合并骨质疏松症的影响

卢广民1㊀周生艳2㊀徐剡3∗

1.临沂市经济技术开发区人民医院,山东临沂276023

2.山东兰陵县人民医院,山东兰陵276024

3.内蒙古医科大学附属医院,内蒙古呼和浩特010070

中图分类号:R587.1㊀㊀文献标识码:A㊀㊀文章编号:1006-7108(2019)01-0103-04

摘要:目的㊀探讨降钙素联合骨化三醇胶丸治疗糖尿病合并骨质疏松症患者对骨代谢㊁骨密度及血糖的影响㊂方法㊀采用配对比较法将我院2011年1月至2015年12月收治的2型糖尿病合并骨质疏松症患者分为接受骨化三醇胶丸治疗的对照组及接受降钙素联合骨化三醇胶丸治疗的观察组,各40例㊂两组均接受基础降糖治疗,观察两组患者治疗前及治疗1年后骨代谢㊁血糖㊁骨密度情况和治疗期间的不良反应㊂骨代谢指标包括骨钙素(bone gamma-carboxyglutamic-acid-containing proteins,BGP)㊁β-胶原片段(beta-crosslaps,β-CTX)㊁25羟基维生素D[25-hydroxyvitamin D,25(OH)D]㊁人骨碱性磷酸酶(bone alkaline phosphatase,BALP)㊁甲状旁腺素(parathyroid hormone,PTH)㊂结果㊀两组治疗前骨代谢指标㊁血糖指标及不同部位骨密度对比,差异无统计学意义(P >0.05),观察组治疗1年后BGP㊁β-CTX㊁BALP㊁PTH 低于同组治疗前及对照组同期(P <0.05),25

(OH)D 及不同部位骨密度均高于同组治疗前及对照组同期(P <0.05),空腹及餐后2h 血糖低于治疗前(P <0.05),但与对照组相当(P >0.05);观察组总有效率(97.50%)高于对照组(80.00%)(P <0.05);两组不良反应发生率对比,差异无统计学意义(P >0.05)㊂结论㊀降钙素联合骨化三醇对糖尿病合并骨质疏松患者疗效显著,可有效改善骨代谢,治疗骨质疏松㊂关键词:降钙素;骨化三醇;糖尿病;骨质疏松;骨代谢;骨密度;血糖

Effects of calcitonin and calcitonin combined with calcitriol capsule on diabetes mellitus complicated with osteoporosis

LU Guangmin 1,ZHOU Shengyan 2,XU Yan 3∗

1.Linyi Economic and Technological Development Zone People s Hospital ,Linyi 276023

2.Shandong Lanling County People s Hospital ,Lanling 276024

3.Affiliated Hospital of Inner Mongolia Medical University ,Mongolia 010070,China ∗Corresponding author :XU Yan ,Email :oycxol @

Abstract :Objective ㊀To investigate the effects of calcitonin combined with calcitriol capsules on bone metabolism ,bone mineral density and blood glucose in patients with diabetes mellitus complicated with osteoporosis ,in order to accumulate experience for the promotion and application of this regimen.Methods ㊀From January 2011to December 2015,paired comparison was used to assign patients with type 2diabetes mellitus and osteoporosis in our hospital to control group receiving calcitriol capsules and to observation group receiving calcitonin combined with calcitriol capsules.There were 40cases in each group and both groups received basic hypoglycemic therapy.Bone metabolism ,blood glucose and bone density were observed before and after 1year of treatment and the adverse reactions during treatment were observed in both groups.Bone metabolic markers assessed include :Bone Gamma-Carboxyglutamic-Acid-Containing Proteins (BGP ),Beta-Crosslaps (β-CTX ),25-hydroxyvitamin D (25-OHVitD ),Human Osteogen Bone Alkaline Phosphatase (BLAP )and parathyroid hormone (PTH ).Results ㊀There were no significant differences in bone metabolism ,blood glucose and bone mineral density at different sites before treatment between the two groups.BGP ,β-CTX ,BLAP and PTH were lower in the observation group after 1year of treatment compared with before treatment and the control group

3

01中国骨质疏松杂志㊀2019年1月第25卷第1期㊀Chin J Osteoporos,January 2019,Vol 25,No.1Published online ㊀doi:10.3969/j.issn.1006-7108.2019.01.019